Table 1. Effect of MGMT Promoter Methylation Status on Survival, According to Random Treatment Assignment.* Promoter Status and Outcome Radiotherapy (N=100) Temozolomide plus Radiotherapy (N=106) Methylated MGMT promoter No. of patients 46 46 Progression-free survival Median duration (mo) 5.9 (5.3–7.7) 10.3 (6.5–14.0) Rate at 6 mo (%) 47.8 (33.4–62.3) 68.9 (55.4–82.4) Hazard ratio for death 1.00 0.48 (0.31–0.75) Overall survival Median duration (mo) 15.3 (13.0–20.9) 21.7 (17.4–30.4) Rate at 2 yr (%) 22.7 (10.3–35.1) 46.0 (31.2–60.8) Hazard ratio for death 1.00 0.51 (0.31–0.84) Unmethylated MGMT promoter No. of patients 54 60 Progression-free survival Median duration (mo) 4.4 (3.1–6.0) 5.3 (5.0–7.6) Rate at 6 mo (%) 35.2 (22.5–47.9) 40.0 (27.6–52.4) Hazard ratio for death 1.00 0.62 (0.42–0.92) Overall survival Median duration (mo) 11.8 (9.7–14.1) 12.7 (11.6–14.4) Rate at 2 yr (%) <2† 13.8 (4.8–22.7) Hazard ratio for death 1.00 0.69 (0.47–1.02)
https://www.nejm.org/doi/pdf/10.1056/NEJMoa043331
- Forums
- ASX - By Stock
- KZA
- TMZ data
TMZ data, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online